Patents
Literature
14 results about "Humanized mouse" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A humanized mouse is a mouse carrying functioning human genes, cells, tissues, and/or organs. Humanized mice are commonly used as small animal models in biological and medical research for human therapeutics. Immunodeficient mice are often used as recipients for human cells or tissues, because they can relatively easily accept heterologous cells due to lack of host immunity. Traditionally, the nude mouse and severe combined immunodeficiency (SCID) mouse have been used for this purpose, but recently the NCG mouse, NOG mouse and the NSG mouse have been shown to engraft human cells and tissues more efficiently than other models. Two mouse strains, called MITRG and MISTRG, were described in which human versions of four genes encoding cytokines important for innate immune cell development are knocked into their respective mouse loci. Such humanized mouse models may be used to model the human immune system in scenarios of health and pathology, and may enable evaluation of therapeutic candidates in an in vivo setting relevant to human physiology.
Construction method of crbn gene humanized mouse model and application thereof
The application discloses a method for constructing a CRBN gene humanized mouse model, which comprises replacing a knockout region of a mouse CRBN gene with a knock-in region of a human CRBN gene, so that the CRBN gene humanized mouse model is constructed, and the CRBN gene of the CRBN gene humanized mouse model is subjected to amino acid substitution of S369C, V380E, I391V and E431D. The application replaces a key functional domain of a mouse endogenous CRBN gene with a corresponding sequence of a human CRBN gene, so that the mouse can express a functional human CRBN protein, thereby solving the problem of lack of sensitivity of a wild-type mouse to a CRBN-dependent drug. The model provides an ideal preclinical experimental platform for studying the efficacy, toxicity and mechanism of action of a CRBN-related drug.
Owner:LIAONING CHANGSHENG BIOTECHNOLOGY CO LTD
Non-HLA matched humanized NSG mouse model with patient-derived xenograft
PendingUS20260185119A1HeterograftsNSG mouse
The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.
Owner:JACKSON LAB THE
An immune system humanized mouse model targeting knockout of plk2 and a construction method and application thereof
Owner:INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
Humanized monoclonal antibodies targeting monkeypox virus B6R protein and their applications
ActiveCN120137013Bimprove bindingGood in vitro neutralizationAntibody ingredientsAntiviralsVirologyBioinformatics
This application relates to humanized monoclonal antibodies against monkeypox virus and their applications. By screening humanized mouse anti-B6R specific binding memory B cells with fully human antibodies, humanized high-neutralizing activity monkeypox virus antibodies B6R-16A1, B6R-21G7, B6R-22D12, B6R-22F9, and B6R-22H1 were obtained. These antibodies have the characteristics of strong binding ability to monkeypox virus, good in vitro neutralization, high affinity, and in vivo protective effect.
Owner:INST OF MICROBIOLOGY CHINESE ACAD OF SCI
A method for tracking and assessing the organ metabolic distribution of platelets based on mitochondrial DNA.
This invention belongs to the field of biotechnology and relates to a method for tracking and assessing the metabolic distribution of platelets in organs based on mitochondrial DNA. Specifically, this invention constructs a humanized mouse model, injects exogenous platelets into the humanized mouse model, and sequences the specific SNVs of the exogenous platelet mitochondrial DNA to trace the metabolic distribution of human platelets or human drug-loaded platelets. The safety is assessed by analyzing the metabolic distribution when human platelets are used as a delivery system.
Owner:SHANGHAI HEMACELL BIOTECHNOLOGY INC
A method for constructing a scleroderma model of pbmc humanized mice
PendingCN122123346AIn-vivo testing preparationsAnimal husbandryPeripheral blood mononuclear cellTissue fibrosis
This invention discloses a method for constructing a PBMC-derived humanized mouse scleroderma model. Human peripheral blood mononuclear cells are transplanted into immunodeficient mice, and a human immune system is reconstructed in the mice. Bleomycin is injected into the local skin of the mice in a round-point manner to induce fibrosis and form a scleroderma model. This application can more comprehensively simulate the complex pathological process of immune abnormalities and tissue fibrosis coexisting in human scleroderma, and provides a more realistic and systematic experimental platform for in-depth exploration of the immune mechanism of this disease.
Owner:SHANGHAI SIXIN PHARM TECH CO LTD
Construction method and application of an nlrp3 humanized mouse model
The application discloses a construction method and application of an NLRP3 humanized mouse model, and belongs to the technical field of genetic engineering. The construction method of the NLRP3 humanized mouse model comprises the step of mutating the 708th amino acid of mouse Nlrp3-201 protein into a non-acidic amino acid; the Ensembl ID of the mouse Nlrp3-201 is ENSMUST00000079476.10. It is verified that the 708th amino acid of the mouse NLRP3 protein is mutated into a non-acidic amino acid (for example, alanine), the NLRP3 of the obtained mutant transgenic mouse is similar to human NLRP3, and cannot be cut by caspase-3, and humanization is realized. The mutant mouse model can better reflect the biological processes such as human inflammasome activation, cell pyroptosis and inflammatory reaction, and provides a more accurate animal model for understanding human diseases and drug screening.
Owner:HUBEI UNIV
A cytokine composition for immunotherapy and a method for preparing the same
PendingCN122167596APeptide/protein ingredientsDigestive systemAntiendomysial antibodiesRegulatory T cell
The application discloses a targeted cytokine composition for immunotherapy and a preparation method thereof. The fusion protein comprises, from N-terminal to C-terminal, an anti-PD-L1 single-domain antibody, a hinge region, a double-mutated human IL-15, a hinge region, an anti-NKG2D single-domain antibody and a double-mutated human IgG1 Fc fragment. In vitro experiments show that the fusion protein can simultaneously bind to double targets, significantly promotes NKG2D-positive CD8-positive T cell proliferation and has weak effect on regulatory T cells, and presents synergistic effect in a tumor-immune cell co-culture system. In vivo pharmacodynamic research shows that in a humanized mouse model, the fusion protein significantly inhibits the growth of colon cancer, the number of CD8-positive T cell and NK cell infiltrations in the tumor is obviously increased, and the effect is better than that of non-targeting and single-targeting controls. The fusion protein provided by the application has long-acting circulation, tumor targeting enrichment and immune cell subpopulation precise regulation functions, and can be used for preparing an antitumor drug.
Owner:GUANGDONG DELITAI BIOMEDICAL TECH CO LTD
Method for producing hematopoietic stem cells derived from differentiated totipotent stem cells, and method for creating a humanized mouse model using the produced hematopoietic stem cells.
The present invention relates to a method for producing hematopoietic stem cells derived from totipotent stem cells, and a method for producing a humanized mouse model using the produced hematopoietic stem cells. According to one aspect, the method for producing hematopoietic stem cells can highly efficiently differentiate hematopoietic stem cells from totipotent stem cells without gene insertion, and optimal differentiation conditions have been confirmed by combining low molecular weight compounds and protein growth factors.
Owner:SUNG KWANG MEDICAL FOUND +1
Construction method of humanized sirpalpha immunodeficient mouse and application thereof in human immune reconstruction
PendingCN122235233AImprove target specificityReduce off-target riskMicroinjection basedStable introduction of DNAPeripheral blood mononuclear cellRAG2
This invention discloses a humanized Sirpα The construction methods of immunodeficient mice and their application in human immune reconstitution belong to the field of medical experimental model construction technology. Rag2 ‑ / ‑ IL2rg ‑ / ‑ Using animals with T, B, and NK cell immune dysfunction caused by mutations as the background strain, sgRNA and dsDNA were specifically designed, and their endogenous components were processed using CRISPR / Cas9 gene editing technology. Sirpα The entire genome was modified to be humanized, thus creating a humanized genome. Sirpα Immunodeficient mice. This method is simple to operate, highly reproducible, and constructs a fully humanized mouse. Sirpα Immunodeficient mice exhibit a higher immunodeficient phenotype and can achieve a higher rate of human T cell chimerism after transplantation with human peripheral blood mononuclear cells, while effectively reducing the risk of graft-host disease.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
A kind of RHO-like protein and its application in constructing retinopathy animal model
The present application belongs to the field of animal models, and relates to a kind of RHO-like protein and its application in the construction of retinal pathological animal model.The present application specifically provides a humanized RHO recombinant protein by replacing the amino acid region encoded by the second exon in the Rho protein of mouse with the amino acid region encoded by the second exon in the human RHO protein.Based on the humanized RHO recombinant protein and the humanized RHO recombinant protein with retinal pathogenic mutation, the present application provides a preparation method of humanized mouse model without carrying RHO pathogenic mutation and humanized mouse model carrying RHO pathogenic mutation.The present application provides a preclinical research platform highly simulating human disease for studying the mechanism of RHO pathogenic mutation leading to retinal degeneration and verifying the effectiveness and safety of gene therapy strategy.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL
Exon-humanized mouse
Provided are a donor vector having an exon-humanized gene in which only exon nucleotide sequences of a mouse gene are replaced with human exon nucleotide sequences, an ES cell in which a mouse endogenous gene is replaced with the donor vector, and a mouse crated by using the ES cell.
Owner:TRANSGENIC INC
An EBV immunogenic polypeptide, its combination and application
This invention provides an EBV immunogenic peptide, combinations thereof, and applications. The EBV immunogenic peptide comprises any of the amino acid sequences shown in SEQ ID NO:7-12 and SEQ ID NO:21. This invention also discloses a kit containing the EBV immunogenic peptide or combinations thereof, as well as other drugs for the prevention and / or treatment of EBV-related diseases, such as NK cells. This invention can achieve durable inhibition of EBV-positive nasopharyngeal carcinoma in humanized mouse models and enhance the infiltration and effector function of T cells and NK cells in the tumor microenvironment.
Owner:SHENZHEN BGI CELL TECH CO LTD
Construction method of double humanized hepatitis b mouse model characterized by t cell immune reconstruction
The application provides a method for constructing a double humanized hepatitis B mouse model characterized by T cell immune reconstruction. The method is characterized by promoting humanized T cell reconstruction, and comprises the steps of constructing a human liver chimeric immunodeficient mouse model, infecting the human liver chimeric immunodeficient mouse with HBV, and implanting human immune cells. The results show that hAlb, HBV DNA and HBsAg can be continuously detected in the blood of the constructed mouse, HBsAg and HBcAg can be detected in the liver, and human immune cell infiltration mainly in the form of CD3+ T cells can be detected in the blood, liver and other organs, thereby forming a double humanized hepatitis B mouse model of the liver and the immune system. The humanized mouse model construction technology of the application can be used to study the interaction mechanism of HBV and immune cells in the process of hepatitis B. The technical scheme provides a good animal model for the research of hepatitis B progression, immune cell exhaustion mechanism and clinical hepatitis B drug treatment.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE